Clinical trials at the Eleanor N. Dana Cancer Center
Consult your medical team to find out whether you are a candidate for one of our clinical trials. Since we are constantly expanding the list of clinical trials we offer, if you don't see your cancer indication listed below please contact the Eleanor N. Dana Cancer Center at 419.383.6644. You can learn more about clinical trials here.
All Cancer Indications
Molecular Target Registry
Breast Cancer
Colorectal Cancer
There are currently no clinical trials available for Colorectal Cancer. For more information, you can contact the Eleanor N. Dana Cancer Center at 419.383.6644.
Gastrointestinal Cancer
A PHASE 3 RANDOMIZED, OPEN-LABEL, MULTICENTER CLINICAL STUDY OF CGT9486+SUNITINIB VS SUNITINIB IN SUBJECTS WITH LOCALLY ADVANCED, UNRESECTABLE, OR METASTATIC GASTROINTESTINAL STROMAL TUMORS
Identifier: NCT05208047
Principal Investigator: Divya Vijendra, MD
Glioblastoma
There are currently no clinical trials available for Glioblastoma. For more information, you can contact the Eleanor N. Dana Cancer Center at 419.383.6644.
Head and Neck Cancer
LUNG CANCER NON SMALL CELL (NSCLC) HEAD AND NECK SQUAMOUS CELL CARCINOMA (SCCHN) UROTHELIAL CARCINOMA BLADDER (UCB)
Principal Investigator: Danae Hamouda, MD
A Phase II Multi-Arm (basket) Trial Investigating the Safety and Efficacy of IO102-IO103 in Combination with Pembrolizumab, as First-line Treatment for Patients with Metastatic Non-Small Cell Lung Cancer (NSCLC), Squamous Cell Carcinoma of Head and Neck (SCCHN), or Metastatic Urothelial Bladder Cancer (mUBC)
Identifier: NCT05077709
Principal Investigator: Danae Hamouda, MD
Kidney Cancer
Lung Cancer
Lung Cancer Non Small Cell (NSCLC) Head and Neck Squamous Cell Carcinoma (SCCHN) Urothelial Carcinoma Bladder (UCB)
Identifier: NCT05077709
Principal Investigator: Danae Hamouda, MD
KontRASt-06: An open-label phase II trial evaluating the activity and safety of JDQ443 single-agent as first-line treatment for patients with locally advanced or metastatic KRAS G12C-mutated non-small cell lung cancer with a PD-L1 expression < 1% or a PD-L1 expression ≥ 1% and an STK11 co-mutation.
NCT: 05445843
Principal Investigator: Danae Hamouda, MD
Lymphomas
There are currently no clinical trials available for Lymphoma. For more information, you can contact the Eleanor N. Dana Cancer Center at 419.383.6644.
Melanoma
There are currently no clinical trials available for Lymphoma. For more information, you can contact the Eleanor N. Dana Cancer Center at 419.383.6644.
Pancreatic Cancer
Phase 1B of C3 in Adv Pancreatic and Solid Tumor Cancer
Mechanism: Combination Metformin, Digoxin, Simvastatin (C3) knocks down BIRC5, a dominant cancer stimulatory protein.
Prostate Cancer
A Multi-Center, Prospective, Observational Study of Patients Being Treated with ORGOVYX®
Identifier: NCT05467176
Principal Investigator: Firas Petros, MD
Solid Tumor
Phase 1B of C3 in Adv Pancreatic and Solid Tumor Cancer
Mechanism: Combination Metformin, Digoxin, Simvastatin (C3) knocks down BIRC5, a dominant cancer stimulatory protein.
Urothelial (Renal pelvis, Ureter, and Bladder Cancers)
For more information about the clinical trials that are offered at the Eleanor N. Dana Cancer Center please contact Danielle Mockensturm at 419.383.6925.